These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 31527930)

  • 21. FDA's Dunham delves into drug issues.
    Dunham B; Kahler SC
    J Am Vet Med Assoc; 2014 Apr; 244(7):762-3. PubMed ID: 24783315
    [No Abstract]   [Full Text] [Related]  

  • 22. Accelerated approvals under the microscope.
    Mullard A
    Nat Rev Drug Discov; 2021 Jun; 20(6):409-411. PubMed ID: 34012001
    [No Abstract]   [Full Text] [Related]  

  • 23. The FDA's new clothes.
    Light DW; Lexchin J
    BMJ; 2015 Sep; 351():h4897. PubMed ID: 26399468
    [No Abstract]   [Full Text] [Related]  

  • 24. The FDA's latest draft guidance on accelerated approvals - one step forward, two steps back?
    Benjamin DJ; Lythgoe MP
    Nat Rev Clin Oncol; 2023 Sep; 20(9):577-578. PubMed ID: 37258648
    [No Abstract]   [Full Text] [Related]  

  • 25. Surrogate endpoints and FDA's accelerated approval process.
    Fleming TR
    Health Aff (Millwood); 2005; 24(1):67-78. PubMed ID: 15647217
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of FDA's Accelerated Approval Program Performance December 1992-December 2021.
    Beakes-Read G; Neisser M; Frey P; Guarducci M
    Ther Innov Regul Sci; 2022 Sep; 56(5):698-703. PubMed ID: 35900722
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Checks and Balances on FDA's Authority.
    Lynch HF; Lurie P; Cohen IG
    JAMA; 2024 Sep; 332(9):705-706. PubMed ID: 38889181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Perspectives. GOP sets its sights on Food and Drug Administration.
    Barnett AA
    Faulkner Grays Med Health; 1995 Feb; 49(8):suppl 1-4. PubMed ID: 10139918
    [No Abstract]   [Full Text] [Related]  

  • 29. FDA restructures new product review centers.
    Bouchie A
    Nat Biotechnol; 2002 Oct; 20(10):960. PubMed ID: 12355100
    [No Abstract]   [Full Text] [Related]  

  • 30. Examining Manufacturing Readiness for Breakthrough Drug Development.
    Dye E; Sturgess A; Maheshwari G; May K; Ruegger C; Ramesh U; Tan H; Cockerill K; Groskoph J; Lacana E; Lee S; Miksinski SP
    AAPS PharmSciTech; 2016 Jun; 17(3):529-38. PubMed ID: 26608693
    [No Abstract]   [Full Text] [Related]  

  • 31. FDA's post-approval studies continue to suffer delays and setbacks.
    Willyard C
    Nat Med; 2014 Nov; 20(11):1224-5. PubMed ID: 25375913
    [No Abstract]   [Full Text] [Related]  

  • 32. The FDA's new oncology office.
    Pazdur R
    Clin Adv Hematol Oncol; 2005 Aug; 3(8):612-3. PubMed ID: 16167044
    [No Abstract]   [Full Text] [Related]  

  • 33. The FDA's definitions, designations, and drug approvals: too daring?
    The Lancet Haematology
    Lancet Haematol; 2018 Aug; 5(8):e321. PubMed ID: 30075830
    [No Abstract]   [Full Text] [Related]  

  • 34. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
    Basile EM; Tolomeo D; Gluck E
    Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Accelerated approval dust begins to settle.
    Mullard A
    Nat Rev Drug Discov; 2011 Oct; 10(11):797-8. PubMed ID: 22037027
    [No Abstract]   [Full Text] [Related]  

  • 36. "Fast tracking" drug approvals: is consumer safety being compromised?
    Jacobsen K
    QRC Advis; 2000 Jun; 16(8):5-9. PubMed ID: 10977137
    [No Abstract]   [Full Text] [Related]  

  • 37. Preserve the FDA's authority.
    Guharoy R
    Am J Health Syst Pharm; 1996 Nov; 53(21):2636, 2638. PubMed ID: 8913395
    [No Abstract]   [Full Text] [Related]  

  • 38. Today's FDA.
    Slater EE
    N Engl J Med; 2005 Jan; 352(3):293-7. PubMed ID: 15659733
    [No Abstract]   [Full Text] [Related]  

  • 39. FDA not NIH can speed new drugs.
    Miller HI
    Nature; 2011 Apr; 472(7342):169. PubMed ID: 21490657
    [No Abstract]   [Full Text] [Related]  

  • 40. Paving the critical path of drug development: the CDER perspective.
    Woodcock J
    Nat Rev Drug Discov; 2014 Nov; 13(11):783-4. PubMed ID: 25359359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.